ASX:CYP Cynata Therapeutics (CYP) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Cynata Therapeutics Stock (ASX:CYP) 30 days 90 days 365 days Advanced Chart Get Cynata Therapeutics alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolume159,853 shsAverage VolumeN/AMarket CapitalizationA$57.60 millionP/E RatioN/ADividend Yield13.95%Price TargetN/AConsensus RatingN/A Company Overview Cynata Therapeutics Limited, together with its subsidiaries, develops and commercializes proprietary induced pluripotent stem cell and mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia. The company's lead therapeutic product candidate is CYP-001, which has completed Phase I clinical trial for the treatment of graft versus host disease. It also develops CYP-004, which is in Phase III clinical trial used for the treatment of osteoarthritis; and CYP-006TK, a novel polymercoated silicon wound dressing for diabetic wounds. In addition, the company develops products for the treatment of asthma, heart attack, coronary artery disease, brain cancer, sepsis, acute respiratory distress syndrome, critical limb ischemia, idiopathic pulmonary fibrosis, and renal transplantation. Cynata Therapeutics Limited has a strategic partnership with Fujifilm to provide clinical and commercial manufacturing services for, and supply of, Cynata's Cymerus therapeutic mesenchymal stem cell products. The company was formerly known as Eco Quest Limited and changed its name to Cynata Therapeutics Limited in October 2013. Cynata Therapeutics Limited was incorporated in 2003 and is based in Cremorne, Australia. Read More Receive CYP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cynata Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address CYP Stock News HeadlinesCynata Therapeutics Ltd Stock Price History - Investing.comJuly 5 at 7:51 AM | investing.comCynata Therapeutics Ltd (51S.SG) - Yahoo FinanceJuly 1, 2025 | finance.yahoo.comPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how to trade it, this phase brings the most potential. We’re now in that window. A free workshop outlines how a proven system is targeting daily wins, passive income, and explosive upside through curated altcoin picks. Whether you're new to crypto or looking to catch the next move with confidence, this is your roadmap. And just for showing up, you’ll receive $10 in real Bitcoin. Don’t miss it.July 5 at 2:00 AM | Crypto Swap Profits (Ad)Cynata Therapeutics Launches InvestorHub to Enhance EngagementMay 21, 2025 | msn.comGraft Versus Host Disease Market is Projected for Substantial Expansion from USD 1.3 Billion in 2023| DelveInsightMarch 13, 2025 | theglobeandmail.comThe ASX players bringing new hope to IPF sufferersMarch 13, 2025 | msn.comCynata's stem cell tech verified in peer-reviewed studyFebruary 4, 2025 | msn.comHealth Check: Pro Medicus founders cashed up for the festive seasonDecember 5, 2024 | msn.comSee More Headlines CYP Stock Analysis - Frequently Asked Questions How were Cynata Therapeutics' earnings last quarter? Cynata Therapeutics Limited (ASX:CYP) posted its quarterly earnings data on Wednesday, February, 27th. The company reported ($0.03) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.03). Cynata Therapeutics had a negative net margin of 420.82% and a negative trailing twelve-month return on equity of 100.01%. What other stocks do shareholders of Cynata Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cynata Therapeutics investors own include Allied Gaming & Entertainment (AGAE), Avino Silver & Gold Mines (ASM), Academy Sports and Outdoors (ASO), Bank of America (BAC), Berkeley Energia (BKY), Global X Cloud Computing ETF (CLOU) and Eaton Vance Tax-Advantaged Global Dividend Opportunities Fund (ETO). Company Calendar Last Earnings2/27/2019Today7/05/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeASX SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolASX:CYP CIKN/A Webwww.cynata.com Phone61 3 9824 5254FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Trailing Twelve Months)A($0.05) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-A$9.74 million Net Margins-420.82% Pretax MarginN/A Return on Equity-100.01% Return on Assets-46.70% Debt Debt-to-Equity RatioN/A Current Ratio5.58 Quick Ratio9.23 Sales & Book Value Annual SalesA$2.32 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow11.93 Book ValueA$0.04 per share Price / BookN/AMiscellaneous Outstanding Shares180,680,000Free FloatN/AMarket CapA$57.60 million OptionableNot Optionable Beta0.93 These 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (ASX:CYP) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredA new rule goes live in July — and the banks are quietly cashing inA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredThe #1 AI Energy StockNearly $600 billion is projected to be spent on AI data centers this year. That's because the ones being bu...Weiss Ratings | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cynata Therapeutics Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Cynata Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.